Biopharmx Corp (NASDAQ:BPMX) announced its quarterly earnings data on Wednesday. The company reported ($0.06) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.06), Yahoo Finance reports. Biopharmx Corp had a negative return on equity of 1,847.04% and a negative net margin of 28,405.26%.

Biopharmx Corp (NASDAQ BPMX) opened at 0.30 on Thursday. The company’s 50 day moving average price is $0.31 and its 200 day moving average price is $0.48. The company’s market cap is $22.24 million. Biopharmx Corp has a 52-week low of $0.19 and a 52-week high of $0.90.

COPYRIGHT VIOLATION NOTICE: This story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/09/14/biopharmx-corp-bpmx-announces-earnings-results.html.

BPMX has been the subject of a number of research reports. Maxim Group reiterated a “buy” rating and issued a $3.00 price objective on shares of Biopharmx Corp in a research report on Friday, June 2nd. Roth Capital set a $3.00 price objective on Biopharmx Corp and gave the stock a “buy” rating in a research report on Saturday, June 3rd. Finally, HC Wainwright set a $3.00 price objective on Biopharmx Corp and gave the stock a “buy” rating in a research report on Thursday, June 15th.

In other Biopharmx Corp news, major shareholder Franklin Resources Inc bought 250,000 shares of Biopharmx Corp stock in a transaction on Tuesday, August 1st. The stock was bought at an average price of $0.34 per share, with a total value of $85,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

An institutional investor recently raised its position in Biopharmx Corp stock. Vanguard Group Inc. lifted its position in shares of Biopharmx Corp (NASDAQ:BPMX) by 324.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,933,747 shares of the company’s stock after buying an additional 1,478,338 shares during the quarter. Vanguard Group Inc. owned approximately 2.61% of Biopharmx Corp worth $927,000 at the end of the most recent quarter.

About Biopharmx Corp

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.